Monday, 16 September 2013

Ranbaxy gains 6%; Nomura says buy but lowers target

Nomura says the correction of 30 percent is an opportunity to buy Ranbaxy Labs. The brokerage house has a buy rating on the stock, but cut its target price to Rs 403 from Rs 490 earlier.

No comments:

Post a Comment